Graphic Packaging Holding Company is a well-known provider of paper packaging solutions for a range of products to food, beverage and other consumer product companies. The company has market cap of $4.03 billion. The Company’s divisions include Paperboard Mills, Americas Paperboard Packaging, Europe Paperboard Packaging, and Corporate and Other. It has a 18.15 P/E ratio. The Paperboard Mills segment includes the Company’s North American paperboard mills, which produce primarily coated unbleached kraft and coated recycled board.
The stock of Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) is a huge mover today! The stock increased 1.85% or $0.05 on March 31, reaching $2.76. About 239,994 shares traded or 78.29% up from the average. Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) has risen 39.27% since August 24, 2016 and is uptrending. It has outperformed by 30.41% the S&P500.The move comes after 8 months positive chart setup for the $27.28 million company. It was reported on Mar, 31 by Barchart.com. We have $3.01 PT which if reached, will make NASDAQ:BNTC worth $2.46 million more.
Ratings analysis reveals 78% of Graphic Packaging Holding Company’s analysts are positive. Out of 9 Wall Street analysts rating Graphic Packaging Holding Company, 7 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $14.50 while the high is $17. The stock’s average target of $16.13 is 25.33% above today’s ($12.87) share price. GPK was included in 12 notes of analysts from September 2, 2015. Citigroup maintained Graphic Packaging Holding Company (NYSE:GPK) rating on Wednesday, July 27. Citigroup has “Buy” rating and $16 target. Bank of America downgraded Graphic Packaging Holding Company (NYSE:GPK) on Monday, October 3 to “Neutral” rating. RBC Capital Markets initiated Graphic Packaging Holding Company (NYSE:GPK) on Friday, September 30 with “Outperform” rating. CLSA initiated the shares of GPK in report on Tuesday, November 22 with “Outperform” rating. As per Monday, January 25, the company rating was upgraded by Macquarie Research. Macquarie Research initiated Graphic Packaging Holding Company (NYSE:GPK) on Tuesday, November 10 with “Neutral” rating. Goldman Sachs initiated it with “Buy” rating and $17 target in Thursday, May 12 report. Jefferies downgraded the stock to “Hold” rating in Friday, January 20 report. The stock of Graphic Packaging Holding Company (NYSE:GPK) earned “Buy” rating by Bank of America on Wednesday, December 7. The rating was initiated by Vertical Research with “Buy” on Wednesday, September 2.
Hoplite Capital Management L.P. holds 4.85% of its portfolio in Graphic Packaging Holding Company for 7.58 million shares. Osterweis Capital Management Inc owns 3.02 million shares or 2.72% of their US portfolio. Moreover, Mrj Capital Inc has 1.98% invested in the company for 248,600 shares. The New Hampshire-based American Trust Investment Advisors Llc has invested 1.73% in the stock. Three Peaks Capital Management Llc, a Colorado-based fund reported 896,433 shares.
The stock increased 0.39% or $0.05 during the last trading session, reaching $12.87. About 1.81 million shares traded. Graphic Packaging Holding Company (NYSE:GPK) has declined 10.85% since August 24, 2016 and is downtrending. It has underperformed by 19.70% the S&P500.
Analysts await Graphic Packaging Holding Company (NYSE:GPK) to report earnings on April, 25. They expect $0.13 EPS, down 35.00% or $0.07 from last year’s $0.2 per share. GPK’s profit will be $40.71M for 24.75 P/E if the $0.13 EPS becomes a reality. After $0.14 actual EPS reported by Graphic Packaging Holding Company for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.
Benitec Biopharma Limited is a biotechnology company. The company has market cap of $27.28 million. The Firm is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property ; development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. It currently has negative earnings. The Company’s In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
